ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...
Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...
Median (range) 6.2 (2.3-15.0) 4.5 (2.0-13.7) 4.3 (0.2-14.1) NOTE. Data are No. (%) unless indicated otherwise. The intention-to-treat analysis set included all patients who underwent random assignment ...
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...
Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in an earlier pre-specified interim analysis. In June, Amgen and China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results